BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 202...
February 04 2021 - 7:00AM
BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq:
BTAI), a clinical-stage biopharmaceutical company utilizing
artificial intelligence approaches to develop transformative
medicines in neuroscience and immuno-oncology, today announced that
an update from its ongoing Phase 1b/2 trial of BXCL701, the
Company's investigational, oral innate immunity activator, in
aggressive forms of prostate cancer will be presented in a poster
session at the virtual 2021 ASCO Genitourinary ("ASCO GU") Cancers
Symposium. ASCO GU is being held from Thursday, February 11, 2021
to Saturday, February 13, 2021.
Poster Presentation Details:
Title: BXCL701, first-in-class oral activator of
systemic innate immunity pathway, combined with pembrolizumab
(Keytruda) in men with metastatic castration-resistant prostate
cancer (mCRPC)Poster Session: Prostate Cancer -
AdvancedTime: Available starting on February 11,
2021 at 8:00 a.m. Eastern TimeAbstract Number:
124
The abstract will be available on the ASCO GU website at
meetinglibrary.asco.org/ on Monday, February 8, 2021 at 5:00 p.m.
ET. At the start of the poster session, the poster will be
available in the “News & Media” section of the Company’s
website at www.bioxceltherapeutics.com.
About BXCL701
BXCL701 is an investigational orally administered innate immune
activator designed to initiate inflammation in the tumor
microenvironment. Approved and experimental immunotherapies often
struggle to address cancers that appear "cold" or uninflamed.
Therefore, BXCL701 may render "cold" tumors "hot," making them more
detectable by the adaptive immune system and thereby facilitating
the development of a strong anti-cancer immune response. BTI's
preclinical data supports BXCL701's synergy with both current
checkpoint inhibitor-based therapies and emerging immunotherapies
directed to activate T-cells, such as IL-2.
This candidate is currently being developed as therapy for
aggressive forms of prostate cancer ("cold" tumor) and advanced
solid tumors that are refractory or treatment naïve to checkpoint
inhibitors ("hot" tumors).
BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical
company focused on drug development that utilizes artificial
intelligence approaches to develop transformative medicines in
neuroscience and immuno-oncology. BioXcel's drug re-innovation
approach leverages existing approved drugs and/or clinically
validated product candidates together with big data and proprietary
machine learning algorithms to identify new therapeutic indices.
BioXcel's two most advanced clinical development programs are
BXCL501, an investigational, proprietary, orally dissolving thin
film formulation of dexmedetomidine for the treatment of agitation
and opioid withdrawal symptoms, and BXCL701, an investigational,
orally administered, systemic innate immunity activator in
development for the treatment of aggressive forms of prostate
cancer and advanced solid tumors that are refractory or treatment
naïve to checkpoint inhibitors. For more information, please visit
www.bioxceltherapeutics.com.
Contact Information:
BioXcel Therapeutics, Inc.
www.bioxceltherapeutics.com
Investor Relations:
Mary ColemanBioXcel Therapeutics, VP of Investment
RelationsMColeman@bioxceltherapeutics.com1.475.238.6837
John GrazianoSolebury
Troutjgraziano@soleburytrout.com1.646.378.2942
Media:
Julia DeutschSolebury
Troutjdeutsch@soleburytrout.com1.646.378.2967
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Sep 2023 to Sep 2024